Trametinib Dimethyl Sulfoxide

Phase 3

Trametinib Dimethyl Sulfoxide is one of 38 therapeutic programs targeting Anaplastic Astrocytoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Anaplastic AstrocytomaActive, not recruiting

Clinical Stage III Cutaneous Melanoma AJCC V8Active, not recruiting

Clinical Stage IV Cutaneous Melanoma AJCC V8Terminated

Stage III Cutaneous Melanoma AJCC V7Active, not recruiting

Anaplastic AstrocytomaPhase 2

Active, not recruiting

Clinical Stage III Cutaneous Melanoma AJCC V8Phase 3

Active, not recruiting

Clinical Stage IV Cutaneous Melanoma AJCC V8Phase 2

Terminated

Stage III Cutaneous Melanoma AJCC V7Phase 2

Active, not recruiting

Competition

Competitive Landscape

36 competitors in Anaplastic Astrocytoma

#DrugCompanyPhaseTrials

Gilenya

Actos

Cialis

Istodax

Ixempra

Paraplatin

Valtrex

GGlaxo Dba Glaxosmithkline

Approved

—8

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—9

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

7 10

Ceenu

AAzurity Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Clinical Stage III Cutaneous Melanoma AJCC V8

NCT02224781

Q1 2027

Phase 2Active, not recruiting

Stage III Cutaneous Melanoma AJCC V7

NCT02196181

Q3 2027

Phase 2Active, not recruiting

Anaplastic Astrocytoma

NCT03919071

Clinical

Trials by Indication[1]

Clinical Stage III Cutaneous Melanoma AJCC v81 trial

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02224781·267 enrolled

Anaplastic Astrocytoma1 trial

A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03919071·58 enrolled

Clinical Stage IV Cutaneous Melanoma AJCC v81 trial

The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma With Elevated LDH

Terminated·EECOG-ACRIN Cancer Research Group·Phase 2·NCT04527549·5 enrolled

Stage III Cutaneous Melanoma AJCC v71 trial

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02196181·280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Trametinib Dimethyl Sulfoxide. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Trametinib Dimethyl Sulfoxide. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: NNational Cancer Institute (NCI)

Trametinib Dimethyl Sulfoxide

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Trials by Indication[1]

Clinical Stage III Cutaneous Melanoma AJCC v81 trial

Anaplastic Astrocytoma1 trial

Clinical Stage IV Cutaneous Melanoma AJCC v81 trial

Stage III Cutaneous Melanoma AJCC v71 trial

References

Drug Info

Quick Facts

Related News